Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
16 oct. 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that...
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
25 juil. 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
Mr. McEnany will Continue to Serve as Catalyst's Non-Executive Chairman of the Board Following his Retirement Nationally Recognized Executive Recruitment Firm has been Retained to Initiate Search...
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
19 déc. 2022 16h10 HE
|
Catalyst Pharmaceuticals, Inc.
Acquisition Expands The Company’s Commercial Portfolio With An Established U.S. Marketed Product Company Remains Dedicated To Growth Within Neurology Through Continued Active Business Development...
Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year
07 nov. 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022
25 oct. 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021
25 oct. 2021 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...